Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …

Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Purpose There is a considerable variability in the level of molecular responses achieved
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …